ClinConnect ClinConnect Logo
Search / Trial NCT06899776

Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Mar 26, 2025

Trial Information

Current as of April 29, 2025

Recruiting

Keywords

Chest Pain Myocardial Infarction Emergency Department

ClinConnect Summary

This clinical trial is looking at a new way to quickly assess chest pain in patients coming to the Emergency Department (ED) who may be experiencing Acute Coronary Syndrome (ACS). Researchers want to see if using a quick blood test called high-sensitivity troponin (hs-cTn) can provide faster results and help doctors make better decisions about patient care. The hope is that this test will reduce the amount of time patients spend in the ED and improve overall care, while also benefiting the hospital financially.

To participate in this study, patients need to be at least 18 years old and have symptoms that suggest they might be having a heart issue, like chest pain, shortness of breath, or other similar discomfort. Participants will receive standard care, which includes having their heart activity monitored through an ECG and having a blood sample taken. However, those with certain serious conditions, such as very unstable vital signs or those already being treated for a heart attack, will not be eligible. If you or a loved one is experiencing chest pain and meets the criteria, this trial could play an important role in improving care for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age greater than or equal to18 years
  • * Symptoms suggestive of acute coronary syndrome:
  • Acute chest, epigastric, neck, jaw or arm pain or discomfort or pressure without apparent non-cardiac source
  • Shortness of breath, nausea, vomiting, fatigue/malaise, or
  • Other equivalent discomfort suggestive of an myocardial infarction (MI)
  • Electrocardiogram (ECG) ordered as part of standard of care
  • At least one troponin collected as standard of care
  • Study specific blood sample collected within ± 5 minutes of clinical draw
  • Exclusion Criteria:
  • ST-segment elevation myocardial infarction (STEMI) Activation
  • Unstable vitals signs: symptomatic hypotension at the time of enrollment (systolic \< 90 mm Hg), tachycardia (HR\>120), bradycardia (HR\<40), and hypoxemia (\<90% pulse-oximetry on room air or normal home oxygen flow rate)
  • Central laboratory hs-cTn testing resulted or in process (\>5 minutes) prior to study accrual
  • Prior enrollment
  • Terminal diagnosis with life expectancy less than 6 months

About Wake Forest University Health Sciences

Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.

Locations

Charlotte, North Carolina, United States

High Point, North Carolina, United States

Winston Salem, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

Simon Mahler, MD, MS

Principal Investigator

Wake Forest University Health Sciences

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported